Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Lucas

Showing results (291-300 of 313) with videos related to

Pageof 32
Sort By:
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic TherapyMatthew J Ehrhardt, Qi Liu, Daniel A Mulrooney, et al.
Fertility and Sterility|March 22, 2026
Semen parameters in unirradiated, alkylating agent exposed childhood cancer survivors in the St. Jude Lifetime Cohort StudyDaniel M Green, Kendrick Li, Raymond W Ke, et al.
Oncotarget|June 19, 2015
Impact of systemic targeted agents on the clinical outcomes of patients with brain metastasesAdam G Johnson, Jimmy Ruiz, Ryan Hughes, et al.
Neuro-Oncology|December 11, 2021
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional studyJohn T Lucas, Christopher L Tinkle, Jie Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|January 6, 2022
Pre- and Posttherapy Risk Factors for Vasculopathy in Pediatric Patients With Craniopharyngioma Treated With Surgery and Proton Radiation TherapyJohn T Lucas, Austin M Faught, Chih Yang Hsu, et al.
Nature Communications|January 23, 2026
Epigenome-wide analysis identifies DNA methylation mediators of treatment-related cardiometabolic risk in survivors of childhood cancerTiffany Eulalio, Yoonji Kim, Xiaoxi Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2022
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/<i>DICER1</i> RegistryKris Ann P Schultz, Anne K Harris, Alexander T Nelson, et al.
The Journal of Extra-Corporeal Technology|July 17, 2020
Development of the Adult ECMO Specialist Certification ExaminationJeffrey B Riley, Mark T Lucas, Keith A Samolyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2021
Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node RadiationMonika L Metzger, Michael P Link, Amy L Billett, et al.
Pageof 32

Showing results (291-300 of 313) with videos related to

Sort By:
Pageof 32
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic TherapyMatthew J Ehrhardt, Qi Liu, Daniel A Mulrooney, et al.
Fertility and Sterility|March 22, 2026
Semen parameters in unirradiated, alkylating agent exposed childhood cancer survivors in the St. Jude Lifetime Cohort StudyDaniel M Green, Kendrick Li, Raymond W Ke, et al.
Oncotarget|June 19, 2015
Impact of systemic targeted agents on the clinical outcomes of patients with brain metastasesAdam G Johnson, Jimmy Ruiz, Ryan Hughes, et al.
Neuro-Oncology|December 11, 2021
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional studyJohn T Lucas, Christopher L Tinkle, Jie Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|January 6, 2022
Pre- and Posttherapy Risk Factors for Vasculopathy in Pediatric Patients With Craniopharyngioma Treated With Surgery and Proton Radiation TherapyJohn T Lucas, Austin M Faught, Chih Yang Hsu, et al.
Nature Communications|January 23, 2026
Epigenome-wide analysis identifies DNA methylation mediators of treatment-related cardiometabolic risk in survivors of childhood cancerTiffany Eulalio, Yoonji Kim, Xiaoxi Meng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2022
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/<i>DICER1</i> RegistryKris Ann P Schultz, Anne K Harris, Alexander T Nelson, et al.
The Journal of Extra-Corporeal Technology|July 17, 2020
Development of the Adult ECMO Specialist Certification ExaminationJeffrey B Riley, Mark T Lucas, Keith A Samolyk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2021
Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node RadiationMonika L Metzger, Michael P Link, Amy L Billett, et al.
Pageof 32